Treatment as the Best Prevention: Twice-Yearly Lenacapavir, a Game Changer in Ending the AIDS Epidemic-Reference-Cited by-同舟云学术

Treatment as the Best Prevention: Twice-Yearly Lenacapavir, a Game Changer in Ending the AIDS Epidemic

Published:2024-08-28 Issue:9 Volume:16 Page:1368
ISSN:1999-4915
Container-title:Viruses
language:en
Short-container-title:Viruses

Author:

Wen Ziyu¹,Shi Minjuan¹,Sun Caijun¹²³⁴^ORCID

Affiliation:

1. School of Public Health (Shenzhen), Sun Yat-sen University, Shenzhen 518107, China

2. Shenzhen Key Laboratory of Pathogenic Microbes and Biosafety, Shenzhen Campus of Sun Yat-sen University, Shenzhen 518107, China

3. Key Laboratory of Tropical Disease Control (Sun Yat-sen University), Ministry of Education, Guangzhou 510080, China

4. State Key Laboratory of Anti-Infective Drug Discovery and Development, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China

Abstract

Despite over four decades of unremitting efforts since the discovery of acquired immunodeficiency syndrome (AIDS)/human immunodeficiency virus (HIV), there remains no cure for HIV nor a vaccine for its prevention [...]

Funder

National Natural Science Foundation of China

Science and Technology Planning Project of Guangdong Province, China

Shenzhen Key Laboratory of Pathogenic Microbes and Biosafety

Sanming Project of Medicine in Shenzhen Nanshan

Key Subject of Nanshan district of Shenzhen for AIDS surveillance and prevention

Publisher

MDPI AG

Link

https://www.mdpi.com/1999-4915/16/9/1368/pdf

Reference10 articles.

1. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women;Baeten;N. Engl. J. Med.,2012

2. On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection;Molina;N. Engl. J. Med.,2015

3. Tenofovir-based preexposure prophylaxis for HIV infection among African women;Marrazzo;N. Engl. J. Med.,2015

4. Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): Final results of a multicentre, prospective, observational study;Rodger;Lancet,2019

5. Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women;Landovitz;N. Engl. J. Med.,2021